Thierry Bernard

First Light Diagnostics develops innovative diagnostic tests that enable rapid and accurate detection of pathogens that can cause life-threatening infections. Our antimicrobial susceptibility tests will help ensure that patients suffering from infection receive appropriate antibiotic treatment options in hours and not days compared to current practices. Leveraging our highly differentiated MultiPath™ technology, our products strive to save lives, lower healthcare costs, improve antibiotic stewardship, and prevent the spread of antibiotic drug-resistance.

Daktari Diagnostics is a healthcare solutions company that enables enhanced disease management in both developed and developing countries. Its portable point-of-care diagnostic platform, with built-in wireless connectivity and an intuitive cloud-based data management system, provides the real-time information necessary to improve clinical outcomes for individual patients and support global disease elimination programs. Daktari’s initial products will target viruses of worldwide significance, including Hepatitis C and HIV. The company recently announced a Hepatitis C partnership with Merck & Co (MSD). A Cambridge, Massachusetts, USA-based, venture-funded technology company, Daktari has assembled an outstanding team of investors, scientists, engineers, and experts in health care delivery. The Company is always interested in motivated individuals with a passion for performance.

HepatoChem is an emerging life sciences company dedicated to the commercialization of our unique approach for producing new chemical entities for metabolism study and drug discovery.

First Light Diagnostics develops innovative diagnostic tests that enable rapid and accurate detection of pathogens that can cause life-threatening infections. Our antimicrobial susceptibility tests will help ensure that patients suffering from infection receive appropriate antibiotic treatment options in hours and not days compared to current practices. Leveraging our highly differentiated MultiPath™ technology, our products strive to save lives, lower healthcare costs, improve antibiotic stewardship, and prevent the spread of antibiotic drug-resistance.

By joining Huttopia, you take part in a common adventure that began 20 years ago aimed at making Huttopia the benchmark company in the ecotourism sector, independent and innovative. Lovers of a certain art of camping and passionate about nature and the great outdoors, Philippe and Céline Bossanne founded Huttopia & Cie in 1999. Combining comfort, quality of services and light facilities, Huttopia quickly established itself as one of the European leaders in Outdoor Hospitality. Since it has brought together people who share a strong vision and common values ​​from the very beginning, the exchange is easy, the cooperation evident and the solidarity natural. The result is quite simply the pleasure of working together, carrying out a common project and sharing the fruits of it. By joining Huttopia, you will be part of a community that is growing every day and which can now give you the opportunity to discover other continents! We are present in Europe, North America and China. Huttopia now has 300 permanent employees and 1,000 seasonal team members who master an integrated chain of know-how, ranging from operations to marketing and sales, from finance to HR, including Information Systems and engineering. development of sites in natural environments. Initiative, autonomy, adventure, commitment, this is what a "Huttopian" and those to come must have!

Daktari Diagnostics is a healthcare solutions company that enables enhanced disease management in both developed and developing countries. Its portable point-of-care diagnostic platform, with built-in wireless connectivity and an intuitive cloud-based data management system, provides the real-time information necessary to improve clinical outcomes for individual patients and support global disease elimination programs. Daktari’s initial products will target viruses of worldwide significance, including Hepatitis C and HIV. The company recently announced a Hepatitis C partnership with Merck & Co (MSD). A Cambridge, Massachusetts, USA-based, venture-funded technology company, Daktari has assembled an outstanding team of investors, scientists, engineers, and experts in health care delivery. The Company is always interested in motivated individuals with a passion for performance.

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. Our mission is to improve antibiotic decision-making and patient outcomes while limiting unnecessary antibiotic use and reducing cost. AdvanDx employs a unique, Whole Cell Analysis (WCA) approach to pathogen identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform. This technology enables fast and highly accurate single cell analysis for bacterial species identification in samples from patients with critical infections. AdvanDx is the market leader in molecular testing of positive blood cultures enabling clinical microbiology labs to report pathogen identification results 48 to 72 hours earlier than with conventional testing methods. When used by physicians and pharmacists to ensure early, appropriate antibiotic therapy for patients with bloodstream infections (a.k.a. septicemia), AdvanDx’s PNA FISH® tests have been shown in clinical studies to reduce patient mortality, shorten length of stay (LOS) and lower hospital costs.

HepatoChem is an emerging life sciences company dedicated to the commercialization of our unique approach for producing new chemical entities for metabolism study and drug discovery.